Summary of the 12th Meeting of the European Forum on antiphospholipid antibodies ONLINE

Lupus ◽  
2021 ◽  
pp. 096120332110550
Author(s):  
Aleksandra Djokovic ◽  
Ljudmila Stojanovich
Keyword(s):  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Research Projects ◽  
Online Forum ◽  
Interactive Communication ◽  
European Forum ◽  
Digital Format ◽  
Set Up ◽  
New Research ◽  
First Time

As a result of the current COVID-19 pandemic, the 12th meeting of the European Forum on Antiphospholipid Antibodies was held in a digital format on 26th March 2021. Even experienced for the first time in a virtual set-up, it kept its strength in continuation of the opportunity for more than 200 physicians from all continents and 20 countries to meet the experts in the field. Contemporary research in the area of antiphospholipid syndrome was presented, and proposals for the new research projects, as a distinguishing feature of the meeting, made a major contribution. Despite challenging times, this meeting enabled the highest number of registered participants to have interactive communication with presenters. This report summarizes major studies and new research projects presented during the online forum meeting.

Sixth meeting of the European Forum on antiphospholipid antibodies. How to improve the understanding of the antiphospholipid syndrome?

Lupus ◽  
2009 ◽  
Vol 18 (1) ◽  
pp. 53-60 ◽  
Author(s):  
Ž Rotar ◽  
B Rozman ◽  
PG de Groot ◽  
M Sanmarco ◽  
Y Shoenfeld ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
European Forum

The Ped-APS Registry: the antiphospholipid syndrome in childhood

Lupus ◽  
2009 ◽  
Vol 18 (10) ◽  
pp. 894-899 ◽  
Author(s):  
T Avčin ◽  
R Cimaz ◽  
B Rozman ◽  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Antiphospholipid Antibodies ◽  
Clinical Laboratory ◽  
Future Research ◽  
Juvenile Systemic Lupus Erythematosus ◽  
Collaborative Project ◽  
European Forum ◽  
International Registry ◽  
Low Prevalence

In recent years, antiphospholipid syndrome (APS) has been increasingly recognised in various paediatric autoimmune and nonautoimmune diseases, but the relatively low prevalence and heterogeneity of APS in childhood made it very difficult to study in a systematic way. The project of an international registry of paediatric patients with APS (the Ped-APS Registry) was initiated in 2004 to foster and conduct multicentre, controlled studies with large number of paediatric APS patients. The Ped-APS Registry is organised as a collaborative project of the European Forum on Antiphospholipid Antibodies and Juvenile Systemic Lupus Erythematosus Working Group of the Paediatric Rheumatology European Society. Currently, it documents a standardised clinical, laboratory and therapeutic data of 133 children with antiphospholipid antibodies (aPL)-related thrombosis from 14 countries. The priority projects for future research of the Ped-APS Registry include prospective enrolment of new patients with aPL-related thrombosis, assessment of differences between the paediatric and adult APS, evaluation of proinflammatory genotype as a risk factor for APS manifestations in childhood and evaluation of patients with isolated nonthrombotic aPL-related manifestations.

European Forum on Antiphospholipid Antibodies: research in progress

Lupus ◽  
2009 ◽  
Vol 18 (10) ◽  
pp. 924-929 ◽  
Author(s):  
PL Meroni ◽  
A Tincani ◽  
ME Alarcón-Riquelme ◽  
Y Shoenfeld ◽  
MO Borghi
Keyword(s):  
Lupus Erythematosus ◽  
Antiphospholipid Antibodies ◽  
Infectious Agents ◽  
Research Projects ◽  
Epitope Specificity ◽  
European Forum ◽  
New Information ◽  
Inflammatory Processes ◽  
Binding Avidity

The research projects of the European Forum on Antiphospholipid Antibodies are representative of how dynamic is this area of investigation. The present review is focused on the most recent projects of the Forum on the aetiopathogenic aspects of the antiphospholipid syndrome (APS). Studies on the genetic background of the APS are ongoing in order to better define the proximity between APS and full-blown systemic lupus erythematosus. However, the analysis of the polymorphisms of genes coding for inflammatory mediators may offer new information on the role of inflammatory processes in triggering thrombotic events as well as the whole susceptibility for developing the vascular manifestations. A systematic and wide detection of serological markers of infectious processes will give new insight on the role of infectious agents in favouring autoimmunity in APS. Owing to the well-known role of vitamin D3 defect in autoimmune disease, the detection of vitamin plasma levels in APS patients will offer the rationale for a possible therapeutic supplementation. Additional projects are aimed to better characterize the diagnostic/prognostic value of antiphospholipid antibodies (aPL) by defining their epitope specificity and binding avidity. Pregnancy complications represent the obstetric side of APS. Research projects are focussed on the role of complement activation in placenta damage and on the potential ability of aPL to affect the fertility. Finally, a study has been planned in order to draw definitive conclusions on the associations between aPL and atherosclerosis.

European attempts for the standardisation of the antiphospholipid antibodies

Lupus ◽  
2009 ◽  
Vol 18 (10) ◽  
pp. 913-919 ◽  
Author(s):  
A Tincani ◽  
M Filippini ◽  
M Scarsi ◽  
M Galli ◽  
PL Meroni
Keyword(s):  
Diagnostic Criteria ◽  
Antiphospholipid Syndrome ◽  
Diagnostic Tests ◽  
Antiphospholipid Antibodies ◽  
Lupus Anticoagulant ◽  
Functional Assay ◽  
European Forum ◽  
Glycoprotein I ◽  
Definition Of ◽  
Major Target

According to the Sydney criteria, antiphospholipid syndrome (APS) diagnosis is closely related to the demonstration of antiphospholipid antibodies (aPL) in patients sera. For this purpose, three different assays are conventionally accepted: lupus anticoagulant (LA), anticardiolipin (aCL) and anti-β2 glycoprotein I (β2GPI) antibodies. LA, described in the 1950s is a coagulation-based functional assay, which indirectly detects the presence of aPL. The aCL ELISA was developed in 1985; the identification of β2GPI as a major target of aPL, allowed the introduction of anti-β2GPI ELISA. Even if the diagnostic criteria for APS have been well defined, the laboratory detection of aPL is not always reproducible for many reasons. To achieve a univocal diagnostic definition of APS, efforts were made to reduce the inter- and/or intra-laboratory variability of the diagnostic tests. In this article, we analyse the studies performed to standardise aPL assays that were developed within the European Forum on Antiphospholipid Antibodies.

scholarly journals Joint Discussion 10 Progress in planetary exploration missions

2006 ◽  
Vol 2 (14) ◽  
pp. 319-320
Author(s):  
Guy Consolmagno
Keyword(s):  
Solar System ◽  
Planetary Exploration ◽  
Research Projects ◽  
Laboratory Studies ◽  
The Earth ◽  
Space Age ◽  
New Research ◽  
First Time

The astronomical study of planets is as old as Galileo's telescope, but in a profound way it was reborn with the advent of the Space Age. By constructing probes capable of leaving the surface of the Earth and traveling to other places in our solar system, sending back data collected from the very places that the astronomers wished to study, for the first time we were freed from the restrictions of observing astronomical objects from afar. These in-situ measurements, in their turn, have inspired countless new research projects back on Earth, from laboratory studies of materials to telescopic observations, of objects and in wavelengths now known to be of astronomical interest, thanks to those probes.

Cobalt/Lewis Acid Catalysis for Hydrocarbofunctionalization of Alkynes via Cooperative C–H Activation

2020 ◽  
Author(s):  
Chang-Sheng Wang ◽  
Sabrina Monaco ◽  
Anh Ngoc Thai ◽  
Md. Shafiqur Rahman ◽  
Chen Wang ◽  
...  
Keyword(s):  
Catalytic System ◽  
Lewis Acid ◽  
Hydrogen Transfer ◽  
Acid Catalysis ◽  
Rate Limiting Step ◽  
Site Selectivity ◽  
Set Up ◽  
Site Selective ◽  
First Time ◽  
Rate Limiting

A catalytic system comprised of a cobalt-diphosphine complex and a Lewis acid (LA) such as AlMe3 has been found to promote hydrocarbofunctionalization reactions of alkynes with Lewis basic and electron-deficient substrates such as formamides, pyridones, pyridines, and azole derivatives through site-selective C-H activation. Compared with known Ni/LA catalytic system for analogous transformations, the present catalytic system not only feature convenient set up using inexpensive and bench-stable precatalyst and ligand such as Co(acac)3 and 1,3-bis(diphenylphosphino)propane (dppp), but also display distinct site-selectivity toward C-H activation of pyridone and pyridine derivatives. In particular, a completely C4-selective alkenylation of pyridine has been achieved for the first time. Mechanistic stidies including DFT calculations on the Co/Al-catalyzed addition of formamide to alkyne have suggested that the reaction involves cleavage of the carbamoyl C-H bond as the rate-limiting step, which proceeds through a ligand-to-ligand hydrogen transfer (LLHT) mechanism leading to an alkyl(carbamoyl)cobalt intermediate.

Sign in / Sign up

Export Citation Format

Share Document